Publikationen in Zusammenarbeit mit Forschern von Charles University in Prague (12)

2024

  1. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

    Haematologica, Vol. 109, Núm. 7, pp. 2239-2249

2023

  1. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

2021

  1. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

    The Lancet Oncology, Vol. 22, Núm. 1, pp. 142-154

2020

  1. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Blood Cancer Journal, Vol. 10, Núm. 9

2019

  1. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    The Lancet, Vol. 394, Núm. 10214, pp. 2096-2107

2018

  1. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalanprednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

    Haematologica, Vol. 103, Núm. 9, pp. 1518-1526

2017

  1. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

    British Journal of Haematology, Vol. 177, Núm. 3, pp. 404-413

  2. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment

    Blood Cancer Journal, Vol. 7, Núm. 4

2016

  1. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

    Cancer, Vol. 122, Núm. 13, pp. 2050-2056

2015

  1. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152

  2. Elotuzumab therapy for relapsed or refractory multiple myeloma

    New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631

2008

  1. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

    Haematologica, Vol. 93, Núm. 3, pp. 431-438